MTBC Medical Transcription Billing Corp

CareCloud Reports Record Full Year 2022 Results

CareCloud Reports Record Full Year 2022 Results

SOMERSET, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- (the “Company” or “CareCloud”) (Nasdaq: CCLD, CCLDP and CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced financial and operational results for the year ended December 31, 2022. The Company’s management will conduct a conference call with related slides today at 8:30 a.m. Eastern Time to discuss these results and management’s outlook for the year.

“2022 was a successful transformational year for CareCloud,” said A. Hadi Chaudhry, CareCloud’s Chief Executive Officer and President. “We launched several new products, including CareCloud Remote for home healthcare and CareCloud Wellness, which expanded our digital health portfolio to provide chronic care management and remote patient monitoring to a rapidly growing user base. The combination of broadening our service offering with these new products and successful focus on organic growth were primary drivers that helped us achieve record bookings in 2022, which is more than double the previous year. We are on a mission to redefine technology-enabled revenue cycle solutions for healthcare and are positioned well to build on this momentum in 2023.”

Full Year 2022 Highlights

  • Revenue of $138.8 million, as compared to $139.6 million in 2021
  • Record GAAP net income of $5.4 million, compared to $2.8 million in 2021
  • Adjusted net income of $16.3 million or $1.07 per share, compared to $18.5 million or $1.24 per share in 2021
  • Record adjusted EBITDA of $22.2 million, an increase of $129,000 over $22.1 million in 2021

Fourth Quarter 2022 Highlights

  • Revenue of $32.5 million, as compared to $37.5 million in Q4 2021
  • GAAP net income of $499,000, compared to $3.5 million in Q4 2021
  • Adjusted net income of $3.9 million, or $0.25 per share
  • Adjusted EBITDA of $5.7 million, as compared to $6.1 million in Q4 2021

Full Year 2022 Financial Results

Revenue for 2022 was $138.8 million, a 1% decline compared to $139.6 million in 2021.

Bill Korn, CareCloud’s Chief Financial Officer remarked, “when we acquired Meridian Medical Management in mid-2020, their two largest clients were health systems which had each been acquired in 2016 and 2018, and were in the process of migrating away from Meridian onto the platforms utilized by their acquirers. We recognized that we could not stop this migration, for which significant money had already been expended, and understood that we would eventually lose this revenue, though we didn’t know how long the migrations would actually take. Both clients finished the majority of their migrations in mid-2022. Our 2021 revenue of $139.6 million would have been $118.1 million excluding these clients, and our 2022 revenue without these clients was $126.7 million. So, excluding these clients from both years, we would have recorded revenue growth of 7% in 2022.”

“Approximately 88% of our 2022 revenue came from technology-enabled business solutions. Clients using our technology-enabled revenue cycle management services represented approximately 52% of our revenue, with over 90% of that revenue coming from clients who also utilized our EHR or practices management software as well as our services. Approximately 12% of our revenue came from clients utilizing our cloud-based software without a services component, and 24% of our revenue came from professional services, such as our medSR professional services geared towards hospitals and large health systems and CareCloud FORCE workforce augmentation. All of these revenue streams leverage the power of our technology and our low-cost, world-class team.”

“Approximately 10% of our revenue was from clients where we are managing their entire medical practice, and approximately 2% of revenue came from other services.”

CareCloud’s GAAP net income was $5.4 million, compared to $2.8 million in 2021. This is CareCloud’s second consecutive year of positive GAAP net income since its IPO in 2014, representing approximately 92% growth year-over-year. GAAP net loss per share was $0.67, based on the net loss attributable to common shareholders, which takes into account the preferred stock dividends declared during the year.

Non-GAAP adjusted net income for 2022 was $16.3 million or $1.07 per share. Non-GAAP adjusted net income excludes non-cash expenses such as depreciation and amortization as well as the gain from the change in contingent consideration.

Adjusted EBITDA was $22.2 million, an increase of $129,000 from $22.1 million last year, despite the loss of revenue from the two large clients which were acquired and who were previously very profitable, and despite increasing our sales and marketing spending by approximately $1 million.

Fourth Quarter 2022 Financial Results

Revenue for the fourth quarter 2022 was $32.5 million, a decrease of 13% from the fourth quarter of 2021, primarily due to the decrease from the two large clients previously mentioned.

Fourth quarter 2022 GAAP net income was $499,000, compared to $3.5 million in the same period last year. “While the management team looks at adjusted EBITDA and cash flow from operations as the primary indicators of whether our business is growing in a sustainable way, achieving positive GAAP profitability for six consecutive quarters is a great indication of our progress,” remarked Bill Korn. GAAP net loss per share for fourth quarter 2022 was $0.22, based on the net income attributable to common shareholders.

Non-GAAP adjusted net income for fourth quarter 2022 was $3.9 million, or $0.25 per share, and is calculated using the end-of-period common shares outstanding. Non-GAAP adjusted net income exceeded the quarterly dividend paid to preferred shareholders.

Adjusted EBITDA for fourth quarter 2022 was $5.7 million, or 17% of revenue, compared to $6.1 million in the same period last year.

Cash Balances and Capital Structure

As of December 31, 2022, the Company had approximately $12.3 million of cash. During the fourth quarter 2022, cash flow from operations was approximately $6.0 million. Our net working capital on December 31, 2022 was approximately $12.3 million.

On December 31, 2022, the Company had 4,526,231 shares of non-convertible Series A Preferred Stock outstanding, and 1,344,128 shares of non-convertible Series B Preferred Stock outstanding. The Series A shares pay cash dividends at the rate of 11% per annum of the $25.00 per share liquidation preference (equivalent to $2.75 annually per share), but they are fully redeemable at the Company’s option at $25.00 per share. During 2022, the Company sold approximately 1.3 million shares of non-convertible Series B Preferred Stock, which is similar to Series A Preferred Stock, but with an 8.75% annual cash dividend. The Company used $20 million of the proceeds from the Series B offering to redeem 800,000 shares of Series A Preferred Stock on March 18, 2022. Series B shares are redeemable at the Company’s option beginning in February 2024.

2023 Guidance

CareCloud is providing the following forward-looking guidance for the fiscal year ending December 31, 2023:

For the Fiscal Year Ending December 31, 2023

Forward-Looking Guidance
Revenue$142 – $146 million 
Adjusted EBITDA$24 – $27 million 



The Company anticipates full year 2023 revenue of approximately $142 to $146 million. Revenue guidance is based on management’s expectations regarding revenues from existing clients, including adoption of CareCloud Wellness which was introduced in 2022, as well as new clients acquired through organic growth. We have excluded the effects of any future acquisitions or tuck-ins, and made assumptions about the timing for new customers going live and the adoption rates of new services. This implies 12% net organic growth from 2022 to 2023, excluding the revenue from the two large clients who were previously acquired and migrated off our services in mid-2022.

Adjusted EBITDA is expected to be $24 to $27 million for full year 2023, which implies growth of approximately 15% from 2022 to 2023, without the effects of any future acquisitions or tuck-ins.

Conference Call Information

CareCloud management will host a conference call today at 8:30 a.m. Eastern Time to discuss the full year 2022 results. The live webcast of the conference call and related presentation slides can be accessed under Events & Presentations at . An audio-only option is available by dialing 201-389-0920 and referencing “CareCloud Fourth Quarter 2022 Earnings Call.” Investors who opt for audio only will need to download the related slides at .

A replay of the conference call with slides will be available approximately one hour after conclusion of the call at the same . An audio replay can also be accessed by dialing 412-317-6671 and providing access code 13736125.

About CareCloud

CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health at .

Follow CareCloud on ,  and .

For additional information, please visit our website at . To view CareCloud’s latest investor presentations, read recent press releases, and listen to interviews with management, please visit .

Use of Non-GAAP Financial Measures

In our earnings releases, prepared remarks, conference calls, slide presentations, and webcasts, we use and discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investor Relations section of our web site at .

Forward-Looking Statements

This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “shall,” “should,” “could,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “seek,” “estimates,” “forecast,” “predicts,” “possible,” “potential,” “target,” or “continue” or the negative of these terms or other comparable terminology.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management's expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the impact of the Covid-19 pandemic on our financial performance and business activities, and the expected results from the integration of our acquisitions.

These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies products and services competitive with ours, and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the Covid-19 virus and the impact it may have on the Company’s operations, the demand for the Company’s services, and economic activity in general.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE CareCloud

Company Contact:

Bill Korn

Chief Financial Officer

CareCloud, Inc.

Investor Contact:

Asher Dewhurst

ICR Westwicke

CARECLOUD, INC.
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2022 AND 2021
($ in thousands, except share and per share amounts)
       
   December 31,   December 31, 
   2022   2021 
         
ASSETS        
Current assets:        
Cash $12,299  $9,340 
Restricted cash  -   1,000 
Accounts receivable - net  14,773   17,006 
Contract asset  4,399   4,725 
Inventory  381   503 
Current assets - related party  16   13 
Prepaid expenses and other current assets  2,785   2,972 
Total current assets  34,653   35,559 
Property and equipment - net  5,056   5,404 
Operating lease right-of-use assets  4,921   6,940 
Intangible assets - net  29,520   30,778 
Goodwill  61,186   61,186 
Other assets  838   981 
TOTAL ASSETS $136,174  $140,848 
LIABILITIES AND SHAREHOLDERS' EQUITY        
Current liabilities:        
Accounts payable $5,681  $5,948 
Accrued compensation  4,248   4,251 
Accrued expenses  4,432   5,091 
Operating lease liability (current portion)  2,273   3,963 
Deferred revenue (current portion)  1,386   1,085 
Deferred payroll taxes  -   934 
Notes payable (current portion)  319   344 
Contingent consideration (current portion)  -   3,090 
Dividend payable  4,059   3,856 
Consideration payable  -   1,000 
Total current liabilities  22,398   29,562 
Notes payable  13   20 
Borrowings under line of credit  8,000   8,000 
Operating lease liability  3,207   4,545 
Deferred revenue  342   341 
Deferred tax liability  525   449 
Total liabilities  34,485   42,917 
COMMITMENTS AND CONTINGENCIES        
SHAREHOLDERS' EQUITY:        
Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,526,231 and 5,299,227 shares at December 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,344,128 shares at December 31, 2022  6   5 
Common stock, $0.001 par value - authorized 35,000,000 shares. Issued 15,970,204 and 15,657,641 shares at December 31, 2022 and December 31, 2021, respectively. Outstanding 15,229,405 and 14,916,842 shares at December 31, 2022 and December 31, 2021, respectively  16   16 
Additional paid-in capital  130,987   131,379 
Accumulated deficit  (25,621)  (31,053)
Accumulated other comprehensive loss  (3,037)  (1,754)
Less: 740,799 common shares held in treasury, at cost at December 31, 2022 and December 31, 2021  (662)  (662)
Total shareholders' equity  101,689   97,931 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $136,174  $140,848 



CARECLOUD, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2022 AND 2021
($ in thousands, except share and per share amounts)
  Three Months Ended  Year Ended  
  December 31,  December 31, 
  2022  2021  2022  2021 
NET REVENUE $32,534  $37,462  $138,826  $139,599 
OPERATING EXPENSES:                
Direct operating costs  19,568   24,200   84,434   86,918 
Selling and marketing  2,474   2,317   9,788   8,786 
General and administrative  5,341   6,459   23,820   24,273 
Research and development  1,150   81   4,401   4,408 
Change in contingent consideration  (200)  (2,515)  (3,090)  (2,515)
Depreciation and amortization  3,039   2,689   11,725   12,195 
Net loss on lease termination, impairment and unoccupied lease charges  210   340   1,138   2,005 
Total operating expenses  31,582   33,571   132,216   136,070 
OPERATING INCOME  952   3,891   6,610   3,529 
OTHER:                
Interest income  19   5   41   15 
Interest expense  (102)  (181)  (405)  (455)
Other expense - net  (337)  (16)  (637)  (96)
INCOME BEFORE PROVISION FOR INCOME TAXES  532   3,699   5,609   2,993 
Income tax provision  33   177   177   157 
NET INCOME $499  $3,522  $5,432  $2,836 
                 
Preferred stock dividend  3,855   3,644   15,517   14,052 
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $(3,356) $(122) $(10,085) $(11,216)
                 
Net loss per common share: basic and diluted $(0.22) $(0.01) $(0.67) $(0.77)
Weighted-average common shares used to compute basic and diluted loss per share  15,224,347   14,900,391   15,109,587   14,541,061 



CARECLOUD, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
($ in thousands)
       
   2022   2021 
OPERATING ACTIVITIES:        
 Net income $5,432  $2,836 
 Adjustments to reconcile net income to net cash provided by operating activities:        
 Depreciation and amortization  12,318   12,676 
 Lease amortization  3,286   3,574 
 Deferred revenue  302   (72)
 Provision for doubtful accounts  740   890 
 Provision for deferred income taxes  76   289 
 Foreign exchange loss (gain)  610   (16)
 Interest accretion  596   857 
 Loss on sale of assets  -   172 
 Stock-based compensation expense  4,914   5,396 
 Change in contingent consideration  (3,090)  (2,515)
 Adjustment of goodwill  -   36 
 Changes in operating assets and liabilities, net of businesses acquired:        
    Accounts receivable  1,493   (620)
    Contract asset  326   (620)
 Inventory  122   (104)
 Other assets  619   921 
 Accounts payable and other liabilities  (6,593)  (10,366)
 Net cash provided by operating activities  21,151   13,334 
INVESTING ACTIVITIES:        
 Purchases of property and equipment  (2,588)  (2,928)
 Capitalized software  (9,179)  (7,636)
 Cash paid for acquisition (net)  -   (12,582)
 Net cash used in investing activities  (11,767)  (23,146)
FINANCING ACTIVITIES:        
 Preferred stock dividends paid  (15,314)  (14,437)
 Settlement of contingent obligation  (1,000)  - 
 Settlement of tax withholding obligations on stock issued to employees  (1,197)  (2,123)
 Repayments of notes payable  (1,003)  (1,045)
 Financing and stock issuance costs  (32)  (80)
 Proceeds from exercise of warrants  -   6,435 
 Proceeds from issuance of Series B Preferred Stock, net of expenses  30,901   - 
 Proceeds from issuance of common stock, net of expenses  -   2,731 
 Redemption of Series A Preferred Stock  (20,005)  - 
 Proceeds from line of credit  25,500   26,000 
 Repayment of line of credit  (25,500)  (18,000)
 Net cash used in financing activities  (7,650)  (519)
EFFECT OF EXCHANGE RATE CHANGES ON CASH  225   (254)
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH  1,959   (10,585)
CASH AND RESTRICTED CASH - Beginning of the year  10,340   20,925 
CASH AND RESTRICTED CASH - End of the year $12,299  $10,340 
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:        
 Preferred stock cancelled in connection with an acquisition $-  $(4,000)
 Contingent consideration at fair value at acquisition date $-  $5,605 
 Dividends declared, not paid $4,059  $3,856 
 Purchase of prepaid insurance with assumption of note $695  $967 
SUPPLEMENTAL INFORMATION - Cash paid during the year for:        
   Income taxes $153  $282 
   Interest $162  $103 



RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

TO COMPARABLE GAAP MEASURES (UNAUDITED)

The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”

While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.

Adjusted EBITDA to GAAP Net Income

Set forth below is a reconciliation of adjusted EBITDA to our GAAP net income.

  Three Months Ended December 31,  Year Ended December 31, 
  2022  2021  2022  2021 
  ($ in thousands) 
Net revenue $32,534  $37,462  $138,826  $139,599 
                 
GAAP net income  499   3,522   5,432   2,836 
                 
Provision for income taxes  33   177   177   157 
Net interest expense  83   176   364   440 
Foreign exchange loss / other expense  353   73   712   241 
Stock-based compensation expense  1,515   1,390   4,914   5,396 
Depreciation and amortization  3,039   2,689   11,725   12,195 
Transaction and integration costs  152   246   876   1,364 
Net loss on lease termination, impairment and unoccupied lease charges  210   340   1,138   2,005 
Change in contingent consideration  (200)  (2,515)  (3,090)  (2,515)
Adjusted EBITDA $5,684  $6,098  $22,248  $22,119 



Non-GAAP Adjusted Operating Income
to GAAP Operating Income

Set forth below is a reconciliation of our non-GAAP adjusted operating income and non-GAAP adjusted operating margin to our GAAP operating income and GAAP operating margin.

  Three Months Ended December 31,  Year Ended December 31, 
  2022  2021  2022  2021 
  ($ in thousands) 
Net revenue $32,534  $37,462  $138,826  $139,599 
                 
GAAP net income  499   3,522   5,432   2,836 
Provision for income taxes  33   177   177   157 
Net interest expense  83   176   364   440 
Other expense - net  337   16   637   96 
GAAP operating income  952   3,891   6,610   3,529 
GAAP operating margin  2.9%  10.4%  4.8%  2.5%
                 
Stock-based compensation expense  1,515   1,390   4,914   5,396 
Amortization of purchased intangible assets  1,391   1,801   6,277   8,880 
Transaction and integration costs  152   246   876   1,364 
Net loss on lease termination, impairment and unoccupied lease charges  210   340   1,138   2,005 
Change in contingent consideration  (200)  (2,515)  (3,090)  (2,515)
Non-GAAP adjusted operating income $4,020  $5,153  $16,725  $18,659 
Non-GAAP adjusted operating margin  12.4%  13.8%  12.0%  13.4%



Non-GAAP Adjusted Net Income
to GAAP Net Income

Set forth below is a reconciliation of our non-GAAP adjusted net income and non-GAAP adjusted net income per share to our GAAP net income and GAAP net loss per share.

  Three Months Ended December 31,  Year Ended December 31, 
  2022  2021  2022  2021 
  ($ in thousands, except for per share amounts) 
GAAP net income $499  $3,522  $5,432  $2,836 
                 
Foreign exchange loss / other expense  353   73   712   241 
Stock-based compensation expense  1,515   1,390   4,914   5,396 
Amortization of purchased intangible assets  1,391   1,801   6,277   8,880 
Transaction and integration costs  152   246   876   1,364 
Net loss on lease termination, impairment and unoccupied lease charges  210   340   1,138   2,005 
Change in contingent consideration  (200)  (2,515)  (3,090)  (2,515)
Income tax expense related to goodwill  14   150   75   290 
Non-GAAP adjusted net income $3,934  $5,007  $16,334  $18,497 
                 
End-of-period shares  15,229,405   14,916,842   15,229,405   14,916,842 
                 
Non-GAAP adjusted net income per share $0.25  $0.34  $1.07  $1.24 



For purposes of determining non-GAAP adjusted net income per share, we used the number of common shares outstanding as of December 31, 2022 and 2021, respectively.

  Three Months Ended December 31,  Year Ended December 31, 
  2022  2021  2022  2021 
GAAP net loss attributable to common shareholders, per share $(0.22) $(0.01) $(0.67) $(0.77)
Impact of preferred stock dividend  0.25   0.25   1.03   0.96 
Net income per end-of-period share  0.03   0.24   0.36   0.19 
                 
Foreign exchange loss / other expense  0.02   0.01   0.05   0.02 
Stock-based compensation expense  0.10   0.09   0.32   0.36 
Amortization of purchased intangible assets  0.09   0.12   0.41   0.60 
Transaction and integration costs  0.01   0.02   0.06   0.09 
Net loss on lease termination, impairment and unoccupied lease charges  0.01   0.02   0.07   0.13 
Change in contingent consideration  (0.01)  (0.17)  (0.20)  (0.17)
Income tax expense related to goodwill  0.00   0.01   0.00   0.02 
Non-GAAP adjusted earnings per share $0.25  $0.34  $1.07  $1.24 
                 
End-of-period common shares  15,229,405   14,916,842   15,229,405   14,916,842 
In-the-money warrants and outstanding unvested RSUs  598,245   684,528   598,245   684,528 
Total fully diluted shares  15,827,650   15,601,370   15,827,650   15,601,370 
Non-GAAP adjusted diluted earnings per share $0.25  $0.32  $1.03  $1.19 



Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of CareCloud and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

Management uses adjusted EBITDA, adjusted operating income, adjusted operating margin, and non-GAAP adjusted net income to provide an understanding of aspects of operating results before the impact of investing and financing charges and income taxes. Adjusted EBITDA may be useful to an investor in evaluating our operating performance and liquidity because this measure excludes non-cash expenses as well as expenses pertaining to investing or financing transactions. Management defines “adjusted EBITDA” as the sum of GAAP net income (loss) before provision for (benefit from) income taxes, net interest expense, other (income) expense, stock-based compensation expense, depreciation and amortization, integration costs, transaction costs, impairment charges and changes in contingent consideration.

Management defines “non-GAAP adjusted operating income” as the sum of GAAP operating income (loss) before stock-based compensation expense, amortization of purchased intangible assets, integration costs, transaction costs, impairment charges and changes in contingent consideration, and “non-GAAP adjusted operating margin” as non-GAAP adjusted operating income divided by net revenue.

Management defines “non-GAAP adjusted net income” as the sum of GAAP net income (loss) before stock-based compensation expense, amortization of purchased intangible assets, other (income) expense, integration costs, transaction costs, impairment charges, changes in contingent consideration, any tax impact related to these preceding items and income tax expense related to goodwill, and “non-GAAP adjusted net income per share” as non-GAAP adjusted net income divided by common shares outstanding at the end of the period, including the shares which were issued but are subject to forfeiture and considered contingent consideration.

Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.

In addition to items routinely excluded from non-GAAP EBITDA, management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

Foreign exchange / other expense. Other expense is excluded because foreign currency gains and losses and other non-operating expenses are expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expense is partially outside of our control. Foreign currency gains and losses are based on global market factors which are unrelated to our performance during the period in which the gains and losses are recorded.

Stock-based compensation expense. Stock-based compensation expense is excluded because this is primarily a non-cash expenditure that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred. Stock-based compensation expense includes cash-settled awards based on changes in the stock price.

Amortization of purchased intangible assets. Purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

Transaction costs. Transaction costs are upfront costs related to acquisitions and related transactions, such as brokerage fees, pre-acquisition accounting costs and legal fees, and other upfront costs related to specific transactions. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Integration costs. Integration costs are severance payments for certain employees relating to our acquisitions and exit costs related to terminating leases and other contractual agreements. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Net loss on lease termination, impairment and unoccupied lease charges. Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as a result of an early lease termination. Impairment charges represent charges recorded for a leased facility no longer being used by the Company and a non-cancellable vendor contract where the services are no longer being used. Unoccupied lease charges represent the portion of lease and related costs for vacant space not being utilized by the Company. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Changes in contingent consideration. Contingent consideration represents the amount payable to the sellers of certain acquired businesses based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period, and changes arise from changes in the forecasted revenues of the acquired businesses.

Income tax expense related to goodwill. Income tax expense resulting from the amortization of goodwill related to our acquisitions represents a charge to record the tax effect resulting from amortizing goodwill over 15 years for tax purposes. Goodwill is not amortized for GAAP reporting. This expense is not anticipated to result in a cash payment.



EN
02/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medical Transcription Billing Corp

 PRESS RELEASE

CareCloud Announces Leadership Realignment to Drive 2025 Growth Strate...

CareCloud Announces Leadership Realignment to Drive 2025 Growth Strategy Focused on Accelerating Technology Innovation, Revenue Growth, and Enhancing Client Experience SOMERSET, N.J., Dec. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CCLD, CCLDP, CCLDO), a leading provider of healthcare technology and generative AI solutions for medical practices and health systems nationwide, today announced a strategic realignment of its leadership team, effective January 1, 2025. A. Hadi Chaudhry and Stephen Snyder will serve as Co-CEOs, with Crystal Williams appointed as President. “We are thrilled to ann...

 PRESS RELEASE

CareCloud Files Special Meeting Proxy to Accelerate Growth

CareCloud Files Special Meeting Proxy to Accelerate Growth SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- (the “Company” or “CareCloud”) (Nasdaq: CCLD CCLDO, CCLDP), a leader in healthcare information technology solutions for medical practices and health systems nationwide, today announced the solicitation of proxies from its common stock (the “Common Stock”) shareholders to approve an increase in its authorized shares. This increase is designed to support the Company’s growth initiatives and corporate objectives. Focus on Growth Mahmud Haq, Founder and Executive Chairman of CareClo...

 PRESS RELEASE

CareCloud Reports Third Quarter 2024 Results

CareCloud Reports Third Quarter 2024 Results Pays Off Credit Line, Plans to Resume Preferred Dividends in Q1 2025 SOMERSET, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, announced financial and operational results for the quarter ended September 30, 2024 including that it has fully paid its credit line and that it plans to resume dividends on its Series A and B Preferred Stock on March 15, 2025. The Company’s management will conduct a ...

 PRESS RELEASE

CareCloud Pays Off Credit Line, Signs an Updated Credit Facility Agree...

CareCloud Pays Off Credit Line, Signs an Updated Credit Facility Agreement SOMERSET, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- -- (the “Company”) (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that it has fully paid down its credit facility line with Silicon Valley Bank (“SVB”), achieving a key 2024 objective. Additionally, CareCloud requested and secured a reduction in its borrowing fees and lowered its overall revolving credit facility limit. “We are thrilled to have reached this import...

 PRESS RELEASE

CareCloud To Announce Third Quarter 2024 Results on November 12, 2024

CareCloud To Announce Third Quarter 2024 Results on November 12, 2024 SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, will release its financial results for the quarter ended September 30, 2024 before the market opens on Tuesday, November 12, 2024. The Company will follow with a conference call for investors at 8:30 a.m. Eastern Time. The live webcast of the conference call and related presentation slides can be accessed at . An audio-only op...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch